







Reprints not avaiEfficacy and tolerability of intralesional
bleomycin in dermatology:
A systematic reviewLiora Bik, MD,a Tobias Sangers, MD,a Karin Greveling, MD, PhD,a Errol Prens, MD, PhD,a
Merete Haedersdal, MD, PhD, DMSc,b and Martijn van Doorn, MD, PhDa
Rotterdam, the Netherlands; and Copenhagen, DenmarkBleomycin is widely used as an off-label treatment for various dermatologic indications. However, a
much-needed critical appraisal of the currently available evidence is lacking. We therefore evaluated the
quality of clinical evidence for the efficacy and safety of intralesional bleomycin treatment for dermatologic
indications with the aim to provide evidence-based recommendations for clinical practice. The PubMed,
Embase, Medline Ovid, Web of Science, Cochrane Central, and Google Scholar databases were
systematically searched. Two authors independently selected relevant studies according to predefined
inclusion and exclusion criteria. We assessed the methodologic quality with the Cochrane Collaboration
risk-of-bias assessment tool and selected 10 randomized clinical trials and 15 clinical controlled trials.
Treatment indications included common warts, nonmelanoma skin cancer, cutaneous metastases, keloid
and hypertrophic scars, and hemangioma. Intralesional bleomycin treatment showed significantly higher
cure rates for warts compared with other treatments. Local adverse events included erythema, blackening,
eschar formation, and superficial ulceration. None of the studies reported systemic adverse events.
Methodologic quality of the studies was generally low. Consequently, no firm recommendations can be
made for intralesional bleomycin treatment in clinical practice. However, this review suggests that
intralesional bleomycin is a successful and well-tolerated treatment for recalcitrant warts. ( J Am Acad
Dermatol https://doi.org/10.1016/j.jaad.2020.02.018.)
Keywords: bleomycin; cutaneous metastases; dermatology; drug response; efficacy; electrochemotherapy;
hemangioma; hypertrophic scars; intralesional; keloid; nonmelanoma skin cancer; safety; systematic review.B
leomycin has been approved as cytostatic
drug for the treatment of squamous cell
carcinoma of head, neck, and external
genitalia in dermatology.1,2 In clinical practice,
however, bleomycin is also used off-label for various
other dermatologic indications.
Bleomycin is an antineoplastic antibiotic derived
from Streptomyces verticillus.3 Multiple subtypes
(A1-6 and B1-5) are available, of which bleomycin
A2 and B2 are most commonly used in clinical
practice. The latter subtypes are hydrophilic and
have a metal binding core that is the key factor in the
mechanism of action. Bleomycin is primarily
eliminated by renal excretion and to a lesser extent
by the bleomycin hydrolase (BMH) enzyme.4 BMHtment of Dermatology, Erasmus MC University
r, Rotterdama; and the Department of Derma-
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lable from the authors.shows the highest activity in bone marrow and is
least active in the lungs and skin, with consequently
more bleomycin-related toxicity in the latter tissues.5
Bleomycin’s main mechanism of action is
DNA-strand scissoring. Specifically, in the presence
ofmolecular oxygen, it can oxidizemetal ions such as
Fe21 to Fe31, creating free radicals. Bleomycin binds
to DNA by an electrostatic attraction and breaks the
DNA backbone, which ultimately ends in cell cycle
arrest.5-7 Bleomycin administered to the skin results
in apoptosis of keratinocytes, sclerosing of endothe-
lium cells, and inhibition of collagen synthesis.8
Severe adverse reactions have been reported
after intravenous chemotherapy with bleomycin.
Pulmonary fibrosis has been the most seriousCorrespondence to: Liora Bik, MD, Erasmus MC, Department of
Dermatology, Doctor Molewaterplein 40, 3015 GD Rotterdam,
the Netherlands. E-mail: l.bik@erasmusmc.nl.
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2 Bik et alreported adverse reaction after a total dose
exceeding [400 U.9,10 Severe cutaneous toxicity
has been reported after cumulative dosages of 200
to 300 U, including scleroderma, neutrophilic ec-
crine hidradenitis, and acute generalized exanthem-
atous pustulosis.10-13
In dermatology, bleomycin is mainly used as anCAPSULE SUMMARY
d This systematic review entails an
overview and methodologic quality
assessment of the currently available
evidence for efficacy and safety of
bleomycin treatment for dermatologic
indications.
d Insufficient evidence was available to
provide firm recommendations for
bleomycin treatment in dermatology.
However, intralesional bleomycin should
be considered as a treatment option for
recalcitrant warts.intralesional treatment, and
the dosage usually does not
















Raynaud phenomenon, peripheral vascular diseases,
and bleomycin intolerance.21
The efficacy and safety of intralesional bleomycin
treatment for dermatologic indications has been
investigated in various clinical trials. To date,
however, a much-needed critical appraisal of the
currently available evidence has been lacking. The
objectiveof this studywas to systematically reviewand
evaluate thequalityof clinical evidence for the efficacy
and safety of intralesional bleomycin treatment for
dermatologic indications and to provide evidence-
based recommendations for clinical practice.
METHODS
In January 2019, we conducted a systematic
literature search for intralesional bleomycin
treatment for dermatologic indications. Relevant
keywords were used to search in PubMed, Embase,
Medline Ovid, Web of Science, Cochrane Central,
and Google Scholar. The systematic review was
registered in PROSPERO (CRD42019131934) and
followed the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines for reporting systematic reviews.
The inclusion criteria for selection of the articles
were English language, published from inception to
January 2019, randomized controlled trials (RCTs),
nonrandomized clinical controlled trials (CCTs),
intralesional bleomycin treatments for dermatologic
indications, and reporting clinical outcomes fromintervention. Exclusion criteria were preclinical
studies, monotherapy with intravenous or topical
bleomycin, and case series with fewer than 10
patients. The primary outcome measure was effi-
cacy, and the secondary outcome measure was
safety.
Selection of the articles was performed indepen-
dently by 2 authors (L.B. and
T.S.). Articleswerepreselected
based on the title and abstract.
The final selection was based
on full-text assessment.
Reference lists of selected
articles were screened for
additional relevant studies.
Standardized data extraction
of the included studies was
performed independently by
2 authors (L.B. and T.S.). The
dosage of bleomycinwas con-
verted to United States
Pharmacopeia units (U): 1 U
represents 1 mg (by potency)
or 1000 international units
(IU).22Methodologic quality was independently evalu-
ated according to the Cochrane Collaborations
risk-of-bias assessment tool. Disagreement between
the 2 authors was resolved by discussion and
involved a third author when necessary.
RESULTS
Study characteristics
The data search returned 2672 references.
Duplicates were removed. The remaining 1647
references were screened based on title and abstract,
whereupon 1531 references were excluded. Full
texts of 116 references were obtained, and the
inclusion and exclusion criteria were used to select
25 studies for this review (Fig 1).
The included studies are 10 RCTs and 15 CCTs
published between 1979 and 2018, comprising a
total of 1130 patients. The studies investigated
intralesional bleomycin treatments for the following
dermatologic indications: common warts, nonmela-
noma skin cancer, cutaneous metastases, keloid,
hypertrophic scars, hemangioma, and other indica-
tions. Described routes of administration included
needle injections, jet injector, microneedling pen,
multipuncture technique, and a bleomycin-covered
microneedle patch.
Common warts
Fourteen studies with a total of 584 patients
investigated intralesional bleomycin in 2657
Abbreviations used:
RCT: randomized controlled trial
CCT: clinical controlled trial
PROSPERO: International prospective register of
systematic reviews
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summarized in Table I.19,23-35
Intralesional bleomycin injections resulted in
significantly higher complete cure rates than saline
injection or cryotherapy (P \ .05).19,23-30
Administration of intralesional bleomycin via a
microneedling pen showed comparable cure rates
as intralesional bleomycin injections (P = .474), but
fewer patients reported pain (20% vs 100%;
P = .001).31 A bleomycin-covered microneedle patch
resulted in comparable complete cure rates
compared with cryotherapy but with significantly
lower pain scores on a visual analog scale (0.486 0.5
vs 7.29 6 0.13; P\ .0001).32
Use of a local electroporation procedure after
bleomycin injections resulted in significantly higher
complete cure rates than bleomycin alone
(P = .0015).33 During electroporation, electric pulses
were generated with electrodes at the lesion site to
increase cellular drug uptake.
One study showed significantly higher response
rates in the placebo groups than in the group
receiving bleomycin injections administered with a
jet injector (P = .018).34 The authors did not provide a
specific explanation.
Patients who had received a transplant and were
taking immunosuppressant drugs and patients
without a transplant showed significantly higher
complete cure rates for intralesional bleomycin
injections than for placebo (P \ .0001). However,
transplant recipients showed lower complete cure
rates than patients without a transplant.27 No
difference in complete cure rates was observed
between different dosages of bleomycin injections
(0.25, 0.50, or 1 U/mL) (no P value reported).35
Overall, plantar warts were more resistant to
bleomycin treatment than warts on other anatomic
locations.19,25,26,35Nonmelanoma skin cancer
One study including 113 patients investigated intra-
lesional bleomycin with local electroporation in 113
nonmelanoma skin cancer tumors (Table II).14,20,36-44
This study showed a higher sustained completeresponse rate for electroporation with biphasic pulses
of 50 1 50 s than for electroporation with biphasic
pulses of 25 1 25 s after intralesional bleomycin
administration (no statistical test reported).36
Cutaneous metastases
Three studies including a total of 93 patients
investigated intralesional bleomycin with local
electroporation in 390 cutaneous metastases
(Table II). Intralesional bleomycin, followed by local
electroporation, showed significantly higher
response rates in metastases of melanoma
(P = .017) compared with intralesional bleomycin
alone (P = .002).37,38 For cutaneous metastases of
melanoma and nonmelanoma cancers, similar
response rates have been reported for intralesional
bleomycin, intravenous bleomycin, and intralesional
cisplatin, all followed by local electroporation at the
tumor site (P = .09).39
Keloid and hypertrophic scars
Three studies with a total of 191 patients
investigated intralesional bleomycin treatment in
191 keloids and hypertrophic scars (Table II). A
significantly greater improvement on the Vancouver
Scar Scale was reported with intralesional bleomycin
compared with intralesional 5-fluorouracil (5-FU)
or 5-FU combined with triamcinolone acetonide
(TCA; P \ .005).14 Intralesional bleomycin showed
improvement on the Patient and Observer Scar
Assessment Scale comparable to TCA injections in
patients with dark skin color (Fitzpatrick skin types
III to V; no P value reported).20 Bleomycin
multipuncture technique showed better resolution
scores compared with cryotherapy combined
with TCA injections (P = .001).40 No recurrences
were described after intralesional bleomycin
treatment.14,40
Hemangioma
Two studies with a total of 87 patients inves-
tigated intralesional bleomycin in 87 hemangi-
omas (Table II). Intralesional bleomycin showed
significantly better response rates than intrale-
sional TCA injections, but only in nonresponders
to oral propranolol (P = .037).41 No difference in
hemangioma volume reduction was seen be-
tween intralesional bleomycin injections and
oral propranolol in children (no statistical test
reported).42
Other indications
Two studies with a total of 62 patients investigated
76 lesions of other indications for intralesional
bleomycin treatment in dermatology (Table II). In












n = 116 
Studies included in
qualitative synthesis
n = 25 
Records excluded
n = 1531  
Full-text articles excluded
n = 91 
Reasons:
•  Other language than 
   English: n=3
•  Intravenous bleomycin 
   monotherapy: n=2
•  Intramuscular administration
   route: n=1
•  Topical administration route: 
    n=1
•  Preclinical study: n=1
•  Case report with < 10
   patients: n=6
•  Not controlled: n=69
•  Combination treatment: n=2
•  Duplicates: n=6
Fig 1. Flowchart of the exclusion process ending with 25 included studies.
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paring resulted in higher complete cure rates and
pain reduction than callus paring alone (no P value
reported).43 In vulvar intraepithelial neoplasia, intra-
lesional bleomycin injections and topical bleomycin
application showed poor remission rates and high
rates of disease progression (no statistical tests
reported).44Reports of adverse events
One study reported 3 cases of significant adverse
events due to intralesional bleomycin treatment, but
no details were described.29 Local skin reactions,
including erythema, blackening, and eschar forma-
tion were described as part of the therapeutic effect
of bleomycin.* Superficial ulceration was frequently
reported but generally healed with no or minimal
scarring.14,41,42,44 Hyperpigmentation after treatment*References 19, 24, 26-28, 35, 37, 38, 43.was mainly observed in patients with dark skin
types.14,20,40 Pain during or after the procedure, or
both, was reported in 22 of 25 included
studies.14,19,20,23-39,43,44 None of the included studies
reported systemic adverse events.
Methodologic quality of the included studies
Most of the included studies had an unclear risk of
bias for most of the methodologic criteria of the
Cochrane Collaborations risk-of-bias assessment tool
(Fig 2). Only 3 of the 25 included studies used
high-quality randomization sequences,23,30,41 and all
studies lacked concealment of allocation. Poor
methodologic quality was found for blinding,
incomplete outcome data, selective reporting, and
other bias.
DISCUSSION
This systematic review provides an overview of
the clinical studies investigating the efficacy and
safety of intralesional bleomycin for dermatologic
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RCT 24 (118) Intralesional
bleomycin
injection
Not reported 1-33, interval of
3-6 weeks







































































































































CCT 36 (193) Intralesional
bleomycin
injection









Not reported Renal transplant
patients: CR
37% vs 0%,
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CR 78% vs 16%








CR 78% vs 16%
































Not reported 1-43, interval
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RCT 26 (79) Intralesional
bleomycin
injection









Not reported CR 73.5%,
86.7%, 73.3%





































CCT, Clinical controlled trial; CR, complete response rate; No., number; OR, overall response rate (CR 1 PR); PR, partial response rate; RCT, randomized controlled trial; resp., respectively; RR, relative
risk; U, United States Pharmacopeia unit; VAS, visual analog scale.

























Table II. Characteristics and summary of results of included studies on intralesional bleomycin in nonmelanoma skin cancer, cutaneous metastases, keloids


















































Initial CR of 100%
for both groups.
Sustained CR for
BCC 80% vs 100%,


















Gaudy,37 2006 Metastases of
melanoma


















OR 46% vs 25%
resp. ECT or
bleomycin alone
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alone (P = .017)
(P = .12)








Byrne,38 2005 Metastases of
melanoma






















Not reported CR per lesion
72% vs 26%,
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RCT 67 (67) Intralesional
bleomycin
injection






























































































































































































































5-FU, 5-fluorouracil; BCC, basal cell carcinoma; CCT, clinical controlled trial; CR, complete response; ECT, electrochemotherapy; OR, overall response (CR 1 PR); POSAS, Patient and Observer Scar
Assessment Scale; PR, partial response; RCT, randomized controlled trial; RR, relative risk; SCC, squamous cell carcinoma; TCA, Triamcinolone acetonide; U, United States Pharmacopeia unit; VAS,
visual analog scale; VIN, vulvar intraepithelial neoplasia; VSS, Vancouver Scar Scale.
*16 biphasic pulses of 25- 1 25-s duration, spaced at 0.6 cm with a duration-number product of 0.8 milliseconds and a total sequence duration of 9.6 milliseconds.























































































































Amer, 1988 - -
Shumack, 1979 - -
Bunney, 1984
Hayes, 1986
Shummer, 1983 - -
Munkvad, 1983
Al-Nagar, 2019 - -
Sobh, 1991 - -
Soni, 2011 - -
Ryu, 2018
Pasquali, 2017 - -
Studies investigating  non-melanoma skin cancer
Peycheva, 2004 - -
Studies investigating cutaneous metastases
Marty, 2006 - -
Gaudy, 2006
Byrne, 2005 - -
Studies investigating keloid and hypertrophic scars
Kabel, 2016 - -
Payapvipapong, 2015
Naeini, 2006 - -
Studies investigating hemangioma
Pandey, 2018
Thayal, 2012 - -
Studies investigating other indications
Lee, 2014 - -
Robberts, 1980 - -
High risk of bias
Low risk of bias







High risk of bias
Low risk of bias
Unclear risk of bias
BA
Fig 2. Methodologic quality of the included studies according to the Cochrane risk-of-bias
assessment tool. (A) Methodologic quality of the included studies was categorized as high, low,
or unclear risk of bias according to the Cochrane risk-of-bias assessment tool. Overall,
methodologic quality was poor because of an unclear risk of bias for most of the assessed
criteria. (B) Graph summarizing risk of bias of all 25 included studies.
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study design, of which 10 were RCTs. Favorable
efficacy outcomes were reported in 14 of 18 studies
of intralesional bleomycin comparedwith placebo or
other interventions. Methodologic quality was
generally poor, with only 3 of 25 studies using
appropriate randomization sequences and all studies
lacking concealment of allocation. Furthermore,
most studies had an unclear risk of bias for blinding
and incomplete outcome data.
For all included studies, heterogeneity was found
in treatment indication, use of anesthetics, treatment
frequency and dosage, comparative intervention,
outcome measures, and follow-up time. This hetero-
geneity precluded performing a meta-analysis.Intralesional bleomycin treatment generally
showed good results for common warts, keloids,
hypertrophic scars, propranolol-resistant hemangio-
ma, and corns. However, most studies focused on
bleomycin treatment of common warts.
Recommendations for daily clinical practice are
preferably based on adequately powered head-to-
head clinical trials in which the new intervention is
compared against another (gold standard) interven-
tion. In common warts, intralesional bleomycin
showed higher cure rates than cryotherapy.29,30,32
Plantar warts were more recalcitrant, possibly
because of the endophytic character of the
lesions leading to suboptimal drug delivery.19
In keloid and hypertrophic scars, intralesional
J AM ACAD DERMATOL
n 2020
14 Bik et albleomycin treatment resulted in better improve-
ments than cryotherapy, followed by intralesional
TCA, intralesional 5-FU/TCA injection, or intrale-
sional 5-FU alone.14,40 In hemangioma, intralesional
bleomycin was comparable to oral propranolol
treatment but favorable to TCA injections in
propranolol nonresponders.41,42 No head-to-head
clinical trials are available for nonmelanoma
skin cancer, cutaneous metastases, and vulvar
intraepithelial neoplasia.
Topical treatment is a key element in dermato-
logic practice. Topical bleomycin administration
showed poor results, however, because of the
limited penetration of the lipophilic stratum cor-
neum by this hydrophilic drug.44 Intralesional
administration methods provided greater
bleomycin bioavailability in the skin. Needle in-
jections were most often used, but the microneedle
patch and microneedling pen device may be the
least painful techniques.32 One study using a
mechanical jet injector reported poor response rates
in commonwarts. This could be explained by spill of
bleomycin solution due to suboptimal positioning of
the device leading to insufficient dermal drug
delivery.34
Five included studies reported outcomes of
intralesional bleomycin, followed by electroporation
(electrochemotherapy).33,36-39 Electroporation pro-
vides permeabilization of the lipophilic cell mem-
brane, which enhances penetration of bleomycin
into the cytosol and leads to increased cytotoxicity.45
Electrochemotherapy was primarily investigated
in uncontrolled trials focusing on cutaneous
malignancies.46 In all included studies, electroche-
motherapy showed significant higher success rates
than intralesional bleomycin alone for metastases of
melanoma and common warts.33,37,38
Besides electroporation, local anesthetics have
shown to change the cell permeabilization and
increase cellular uptake of bleomycin in vitro.47 In
clinical studies, adding anesthetics to the bleomycin
solution led to higher complete cure rates in
common warts than with bleomycin alone.23,28-31
Strengths and limitations
Strengths of this systematic review include the
use of a comprehensive data search, inclusion of
only controlled studies with appropriate sample
sizes, reporting of outcome measures as effect size
and adverse events, assessment of methodologic
quality, and inclusion of off-label dermatologic
indications.
Limitations of this review are that one-third of the
studies were published before 2000 (1979-1994) with
a lack of statistical analyses, all studies had an unclearrisk of bias for most of the methodologic criteria, and
several studies did not report the number of patients
or lesions and follow-up time.Intralesional bleomycin treatment in clinical
practice
Treatment characteristics, such as efficacy, safety,
tolerability, usability, and also patient preference
are important factors considered in making a
treatment choice. No systemic adverse events were
reported after bleomycin treatment for any of the
dermatologic indications, making this a relatively
well-tolerated treatment. Local pain was reported
during and after the procedure but was evidently
well-tolerated, and cotreatment with local
anesthetics was usually sufficient. With regard to
usability, bleomycin is relatively easy to administer,
requires minimal resources, is inexpensive, and is
widely available, making it a treatment that can be
easily incorporated into daily clinical practice.
Recalcitrant common warts and keloids are
daily treated in our clinic with intralesional bleomy-
cin. A reproducible success is seen using a mixture of
bleomycin (1 U/mL) with lidocaine hydrochloride
(5 mg/mL) in saline (unpublished data). In most
cases, a conventional 30- or 33-gauge needle injec-
tion is used, with a maximum of 2 mL per treatment.
The bleomycin solution should be deposited in the
mid-dermal part of keloids to prevent necrosis or
ulcerations. In warts, however, bleomycin should be
injected in the superficial dermis to induce necrosis.
Intralesional bleomycin treatment is well tolerated,
but patients experience pain for an average of
2.5 days after the injection. A mechanical jet injector
(eg, DermoJet; Akra, Pau, France) is also practical but
has several disadvantages such as risk of aerosol
formation and drug spill. To reduce the risk of
bleomycin inhalation, a pair of wet gauzes is
wrapped around the tip of the device, the operator
and patient wear surgical respirator (3M, St Paul, MN)
and safety glasses, and a laser smoke evacuator is
used to capture any aerosols.CONCLUSIONS
This review provides a systematically conducted
overview and methodologic quality assessment of
the efficacy and safety of intralesional bleomycin
treatment for dermatologic indications. For all
reviewed indications, there was insufficient evidence
to provide firm recommendations for intralesional
bleomycin treatment in clinical practice. However,
this review suggests that intralesional bleomycin is a
successful and well-tolerated treatment option for
recalcitrant warts.
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Bik et al 15Clearly, more head-to-head trials with high
methodologic quality are needed to provide future
evidence-based recommendations for daily clinical
practice. New and less painful administration
methods, such as laser-assisted drug delivery and
needle-free pneumatic injection, should be investi-
gated besides conventional injections for common
warts, keloid, hypertrophic scars, and nonmelanoma
skin cancer.
We thank the biomedical information specialists of
Erasmus MC Rotterdam for their assistance in the electronic
literature search.
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